Background. Viridans streptococcal bacteremia (VSB) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial mortality. Prevention of this serious complication is therefore a high priority. The objective of this study was to evaluate the effect of early vancomycin administration on rates and outcomes of VSB.
Viridans streptococcal bacteremia (VSB) in neutropenic patients with cancer has been reported with increasing frequency over the past 10 years [1] [2] [3] . In patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), VSB occurs most frequently within the first week after stem cell infusion [4, 5] . VSB in these patients is associated with serious complications and has a mortality rate ranging from 6% to 30% [1, 2, 6] . Profound neutropenia and severe mucositis are present in the majority of HSCT recipients with VSB [1, 2, [6] [7] [8] . Other associations include use of quinolones and exposure to trimethoprim-sulfamethoxazole [1, 9] .
Prophylactic vancomycin has been associated with a decreased incidence of early gram-positive bacteremia after allogeneic HSCT [10, 11] . However, in these studies, vancomycin prophylaxis was not effective in reducing mortality. More recently, extensive exposure to vancomycin was associated with infections due to vancomycin-resistant enterococci and with nephrotoxicity [12] [13] [14] .
Fever in the preengraftment period occurs in 180% of HSCT recipients [15] . Empirical antibiotics in this setting are initiated according to standard guidelines. However, inclusion of vancomycin as part of the initial empirical antibiotic regimen is dependent on institutional practices and clinical circumstances.
To our knowledge, the impact of early vancomycin use on the incidence of VSB in the peritransplantation setting has not been examined. Therefore, we analyzed the impact of early vancomycin therapy on the incidence and outcome of VSB in our allogeneic HSCT recipients.
METHODS

Study patients.
The study was approved by the Memorial Sloan-Kettering Cancer Center (MSKCC) Institutional Review Board (New York). From 1 January 1998 through 30 September 2002, 421 patients received 430 HSCTs. The 9 patients with a second HSCT were tabulated as new patients. Patients with VSB occurring from day Ϫ7 to +14 (relative to stem cell infusion) were identified from a computerized microbiology database. VSB was defined as present if there was a single positive result of culture for viridans group streptococci in a sample drawn from a patient because of febrile neutropenia. Clinical characteristics and outcome were extracted from the medical chart, and antimicrobial information was obtained from pharmacy records. Conditioning regimens, prophylaxis for graftversus-host disease, and supportive care for allogeneic HSCT recipients were as per institutional guidelines at MSKCC. A central venous access device was inserted before conditioning by the interventional radiology or surgery services. Standard antifungal prophylaxis included fluconazole and acyclovir, beginning at cytoreduction. Trimethoprim-sulfamethoxazole or pentamidine (in cases of sulfa allergy) were given from day Ϫ7 though Ϫ3 for Pneumocystis prophylaxis. Antimicrobial therapy was initiated because of fever or clinical signs of sepsis. The initial antibiotic regimen for treating fever and neutropenia was ticarcillin-clavulanic acid plus amikacin for adults and cefepime plus amikacin for children. Vancomycin treatment was initiated at the discretion of the treating physician. Mucositis was graded by the oral assessment score as mild (8) (9) (10) (11) (12) , moderate (13) (14) (15) (16) , or severe (17) (18) (19) (20) (21) (22) [16] .
Conditioning regimens containing fractionated total body irradiation (TBI) were administered as follows: thiotepa at 5 mg/kg per day for 2 days and cyclophosphamide at 60 mg/kg per day for 2 days (41%); thiotepa at 5 mg/kg per day for 2 days and fludarabine at 25 mg/m 2 per day for 5 days (15%); cyclophosphamide (9%); or cyclophosphamide and fludarabine (1.4%) (table 1). Non-TBI, all-chemotherapy regimens included busulfan and cyclophosphamide or busulfan and melphalan. Prophylaxis for graft-versus-host disease included methotrexate and cyclosporin A. Recipients of T cell-depleted grafts did not receive additional immunoprophylaxis for graftversus-host disease.
Definitions. "Early vancomycin" administration was defined as administration of у2 doses of vancomycin during day Ϫ7 to +7 after HSCT or prior to the drawing of the culture for viridans streptococci, whichever occurred first.
Antibiotics, including ticarcillin-clavulanic acid, cefepime, ciprofloxacin, and amikacin, were defined as "early" if given before the date of the incident blood culture. Antibiotic therapy initiated on the date of the incident blood culture was defined as "empirical." Antibiotic administration after confirmation of VSB was defined as "specific therapy." "Neutrophil recovery" was defined as an absolute neutrophil count of 11000 neutrophils/mm 3 on 3 consecutive days after transplantation. "Fatal VSB" was defined as death occurring after VSB with clinical signs of sepsis and/or adult respiratory distress syndrome with no other identifiable contributing factor. Statistical analysis. Risk factors for VSB were identified in univariate and multivariate Cox proportional hazard models. The end point was time to diagnosis of VSB. The model was designed to measure the impact of early vancomycin administration. Candidate host variables included age (continuous) or adult age (118 years) versus pediatric, sex, and underlying diagnosis. Transplantation variables included donor type, cytoreductive regimen, and time to neutrophil recovery.
For multivariate analysis, variables were entered into Cox proportional hazard models and sequentially eliminated in a stepwise backward fashion until the remaining variables were statistically significant. Kaplan-Meier analysis was used to analyze survival. Stata, version 7 (Stata), was used for all statistical analyses [17] . The Cuzick and Altman test was used to calculate P for trend across ordered groups.
was considered to P р .05 be statistically significant.
Microbiological testing. Blood samples were obtained from patients and inoculated into 2 BACTECPLUS blood culture bottles with resins: the Aerobic/F and Anaerobic/F (Becton Dickinson). Bottles were incubated at 37ЊC in the BACTEC 9240 blood culture system for 5 days with continuous agitation before being discarded as negative. a-Hemolytic streptococci from positive cultures that were optochin resistant were identified by use of conventional biochemicals and the API 20 STREP identification system (bioMérieux). Antimicrobial susceptibility testing was done with the MicroScan MICroSTREP plus panel (Dade Behring). Penicillin susceptibility was defined as an MIC of р0.125 mg/mL [18] . Viridans streptococci with MICs of penicillin of у0.25 mg/mL are referred to as "nonsusceptible."
RESULTS
Incidence and timing of VSB.
A total of 430 allogeneic HSCTs were performed during the 57-month study period. Characteristics of patients are shown in table 1. Acute leukemia was the most common underlying diagnosis (46.3%). Chronic myelogenous leukemia was the underlying diagnosis in 57 patients (13.3%). Of the patients with chronic myelogenous leukemia, 39 (68.5%) were classified as low risk for transplantrelated mortality or relapse; the remaining 17 (31.5%) beyond the first chronic phase were classified as high risk.
Thirty-two (7.4%) of 430 HSCTs were complicated by early VSB. Thirty (94%) of the 32 patients with VSB had absolute neutrophil count of !1000 neutrophils/mm 3 , and 68% had severe mucositis at the time of VSB. Figure 1 shows the cumulative incidence of VSB per day relative to the day of stem cell infusion (day 0). The median times from infusion of stem cells to development of VSB was 4 days (range, Ϫ5 to +13 days). There was no seasonal or annual variation in the incidence of VSB.
Risk factors for VSB. Three hundred five patients (70.9%) received early vancomycin therapy. The majority of these patients received early vancomycin therapy because of persistent fever or poor clinical response within 3 days of initiating treatment with a b-lactam or aminoglycoside for neutropenic fever. Only 9% received early vancomycin therapy because of a culture yielding gram-positive organisms (most frequently, coagulasenegative staphylococci). Approximately 10% of persons received vancomycin on the date of their first neutropenic fever. Because of the nature of the study, we were unable to determine factors that led to individual clinicians' decisions to include vancomycin in the initial antibiotic regimen for treating febrile neutropenia.
To identify risk factors, we compared the characteristics of those with VSB and those of the other HSCT recipients during the study period (table 2) . Of the 305 patients who received early vancomycin therapy, VSB developed in 1 (0.3%). In contrast, VSB occurred in 31 (24.8%) of the 125 patients who did not receive vancomycin ( ). By univariate analysis, host P ! .001 factors associated with increased risk for VSB were female sex and a diagnosis of chronic myelogenous leukemia. Conditioning with TBI, thiotepa, and fludarabine was associated with increased risk (table 2) . HSCT recipients with underlying acute lymphocytic leukemia had a significantly reduced risk for VSB.
Next, we assessed the effect of vancomycin after we controlled for host-related factors, underlying disease, donor type, stem cell source, and conditioning regimen. All significant variables from univariate analysis were entered into a Cox proportional hazard model. As shown in table 3, early vancomycin administration resulted in a significantly lower rate of VSB. Risk was significantly increased by cytoreduction with TBI, thiotepa, and fludarabine or diagnosis of chronic myelogenous leukemia.
Outcome of VSB. Twenty-six patients with VSB (81%) had у2 sets of blood cultures within 24 h that yielded viridans group streptococci. Clearance of VSB was documented in all cases by negative results of an additional blood culture. Seven (21.9%) of 32 patients with VSB died, at a median of 26 days (range, 12-36 days) from VSB diagnosis because of acute respiratory distress syndrome and multiorgan system failure. The fatality rate of VSB was stable over the 57-month study period. All fatal cases developed during days 1-6 after HSCT (figure 1).
On the basis of the timing of initiation of antibiotics, we defined 4 groups among the 32 patients with VSB (figure 2): those who received early b-lactam therapy with empirical vancomycin therapy added on the date of incident blood culture (group 1; ), those who received early b-lactam therapy n p 8 Figure 2 . Timing of administration of antibiotics among the 32 patients with viridans streptococcal bacteremia (VSB). The date of the incident blood culture (Blood Cx) is indicated by the horizontal arrow. Early, antibiotic therapy given before the date of the incident blood culture; empirical, antibiotic therapy started on the date of the incident blood culture. There was a trend of decreasing mortality rates across groups with progressively earlier initiation of antibiotic regimens including vancomycin ( , by test for trend). P p .04 ). Fourn p 10 teen patients were receiving early b-lactam therapy before the incident blood culture. Eight of the 14 patients started empirical vancomycin therapy on the date of incident blood culture. Eighteen patients started empirical b-lactam therapy on the date of the incident blood culture; 8 of these 18 also started empirical vancomycin therapy. We compared fatality rates among the 4 groups. There was a statistically significant trend of decreasing fatality rates across group 1 through group 4, with progressively earlier initiation of antibiotic regimens including vancomycin ( , by test for trend). After confirmation of P p .04 the viridans streptococci, all patients received specific treatment with vancomycin in addition to the b-lactam and aminoglycoside regimen.
We compared the characteristics of fatal versus nonfatal cases of VSB to examine risk factors for fatal outcome (table 4) . Age, sex, underlying diagnosis, conditioning regimen, rate of severe mucositis, and time to neutrophil engraftment were not different between fatal and nonfatal cases of VSB.
Unexpectedly, fatal outcome was more likely among patients with VSB whose isolates were susceptible to penicillin. Twentythree (72%) the 32 isolates were not susceptible to penicillin (MIC of у0.25 mg/mL). Eleven of the 23 patients with penicillin-nonsusceptible isolates received empirical vancomycin therapy, but no difference in the mortality rate was found (1 of 11 patients who received vancomycin died vs. 2 of 12 who did not receive vancomycin; significant). P p not
DISCUSSION
During the past 2 decades, viridans streptococci have emerged as an important cause of bacteremia in neutropenic patients with cancer [1, 19] . Serious complications include septic shock (7%-18%) and adult respiratory distress syndrome (3%-33%), with an associated mortality rate ranging from 6% to 30% [2, 6, 7, 20] . The incidence of infection appears to be particularly high among neutropenic HSCT recipients. In initial studies by Villablanca et al. [5] and Steiner et al. [20] , 15% of allogeneic HSCT recipients developed VSB. More recent studies have reported a similar incidence [4, 6] . VSB usually occurs within the first 2 weeks of stem cell infusion, at the time of profound neutropenia and severe mucositis. Given the frequency of the infection and its potentially catastrophic outcome, strategies must be developed to prevent this infection.
We studied a large cohort of adult and pediatric patients who underwent allogeneic HSCT to determine the impact of early administration of vancomycin on the incidence and outcome of VSB. The overall incidence of early VSB in the cohort was 7.4%. Although it is not part of a formal treatment pathway, ∼70% of the patients received vancomycin for various indications from the beginning of cytoreduction through day +7. The incidence of VSB was dramatically higher among 125 patients who did not receive early vancomycin therapy than among those who did (24.8% vs. 0.3%; hazard ratio [HR], 0.02;
). The reduction persisted in multivariate analysis that P ! .001 controlled for host and transplantation variables ( ). P ! .001 Female sex and a diagnosis of chronic myelogenous leukemia were identified as risk factors for VSB in our cohort. Ninety percent of VSB cases developed in patients whose cytoreduction contained TBI. Among those who received TBI, VSB occurred more often with conditioning that included thiotepa and fludarabine (24%) rather than thiotepa and cyclophosphamide (24% vs. 6%; HR, 12.8;
). Mucositis of the oral cavity P ! .001 is a well-recognized predisposing factor for VSB [8, 21, 22] . However, the incidence of severe mucositis was similar among recipients of the 2 TBI-based regimens. Fludarabine has been previously associated with opportunistic infections because of T cell dysfunction [23] . To our knowledge, this is the first report that shows an association of fludarabine with peritransplantation VSB. Interestingly, the molecular structure of fludarabine is closely related to cytarabine, a chemotherapeutic agent, associated with increased risk for VSB [24] [25] [26] . When clinical characteristics and early vancomycin administration were controlled for, conditioning with TBI, thiotepa, and fludarabine and a diagnosis of chronic myelogenous leukemia remained significant risks for VSB.
During the study period, ∼15% of 260 isolates of viridans group streptococci from blood samples obtained from non-HSCT recipients at MSKCC were not susceptible to penicillin, compared with 72% of 32 isolates recovered from HSCT recipients (
). All patients with VSB received double-P p .02 antibiotic coverage with ticarcillin-clavulanic acid or cefepime plus amikacin on the date of the incident blood culture. Approximately 50% of patients also received empirical vancomycin therapy on the date of the incident blood culture. All patients received vancomycin after confirmation of viridans group streptococci from the blood cultures. When we looked at the outcome of VSB cases based on the timing of initiation of antibiotics relative to the incident blood culture, we observed that patients who received empirical vancomycin therapy in addition to b-lactam antibiotics had lower fatality rates. This finding is consistent with previous studies suggesting that mortality due to VSB may be higher among patients who are not initially treated with vancomycin [1, 27] . In mid-2002, we implemented the inclusion of vancomycin in the initial antibiotic regimen for treating neutropenic fever in HSCT recipients at risk for VSB. A recent prospective randomized study of 165 patients that compared piperacillin/tazobactam versus piperacillin/tazobactam and vancomycin for persistent fever and neutropenia after 48-60 h of piperacillin/tazobactam treatment did not show any difference in time to defervescence or mortality between the 2 groups. Fifteen episodes of penicillin-susceptible VSB were diagnosed among the study participants, of which only a minority were HSCT recipients [28] .
Previous prospective randomized trials examining vancomycin prophylaxis in HSCT recipients have yielded conflicting results. This probably reflects differences in incidence of infections with gram-positive organisms, sample size, and schedule of vancomycin administration in each health care center. Several studies showed that vancomycin prophylaxis was effective in preventing gram-positive infections after HSCT; however, none could demonstrate a reduction in mortality [10, 11, 29, 30] . Other studies found vancomycin inefficient in preventing infections and raised concerns about the emergence of resistant organisms [31] [32] [33] . To address this concern, we examined the possible effect of vancomycin use on emergence of vancomycinresistant enterococci at MSKCC. During the period 1995-2001, the incidence of vancomycin-resistant enterococcal bacteremia among HSCT recipients remained stable at 9%, with 61% of cases occurring before engraftment [34] . During the period of the present study, the incidence of vancomycin-resistant enterococcal bacteremia during the first 3 months after HSCT was similar for patients who received early vancomycin and those who did not. Furthermore, the Kaplan-Meier probability of 45-day survival was similar for patients who received early vancomycin versus those who did not, when the fatal VSB cases were excluded from the analysis.
Assessment of which HSCT recipients may benefit from targeted prophylaxis will require constant reevaluation, because changes in HSCT practices affect the incidence of VSB. At MSKCC, the incidence of VSB from 1 January 2003 through 28 February 2004 was 2.9%, compared with 7.4% during the study period (not significant). A reduction in use of conditioning regimens containing TBI (from 66% to 35.6%) and fewer patients with a diagnosis of chronic myelogenous leukemia undergoing transplantation (from 13.3% to 3.9%) may partially account for the decrease in incidence of VSB. Interestingly, though, the incidence of VSB among patients conditioned with TBI in the 2003-2004 interval remained 8.1%, similar to the reported 7.4% during the study period. We have recently initiated a randomized trial of vancomycin prophylaxis for HSCT recipients at risk for VSB.
In this large observational cohort study, we show that early administration of vancomycin was highly protective against VSB in neutropenic allogeneic HSCT recipients. The benefits of targeted vancomycin prophylaxis will be investigated in a controlled clinical trial. Institutions with a high incidence of VSB should weigh risks versus the benefits of prophylaxis in the context of their patient population and hospital epidemiology.
